We are a late-clinical-stage precision immunology biopharmaceutical company focused on the discovery and development of best-in-class biomarker-driven immunoregulatory therapeutics.

Our management team has significant experience in the development of immunoregulatory drugs and a proven track record of rapidly and effectively accelerating and improving drug candidates into and through clinical development.

Our lead clinical candidate, omilancor, is a Phase 3-ready first-in-class, oral, once-daily, gut-restricted LANCL2 agonist in Phase 3 development for the treatment of ulcerative colitis (UC) and Crohn’s disease.

We are on a mission to develop safer and more effective therapeutics that address the unmet needs of patients with autoimmune diseases.